SVRA vs. PHAR, DNTH, SIGA, COGT, NUVB, SLN, MLYS, ZYME, WVE, and ANAB
Should you be buying Savara stock or one of its competitors? The main competitors of Savara include Pharming Group (PHAR), Dianthus Therapeutics (DNTH), SIGA Technologies (SIGA), Cogent Biosciences (COGT), Nuvation Bio (NUVB), Silence Therapeutics (SLN), Mineralys Therapeutics (MLYS), Zymeworks (ZYME), Wave Life Sciences (WVE), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical preparations" industry.
Pharming Group (NASDAQ:PHAR) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking.
In the previous week, Pharming Group and Pharming Group both had 5 articles in the media. Savara's average media sentiment score of 0.56 beat Pharming Group's score of 0.39 indicating that Pharming Group is being referred to more favorably in the media.
Savara received 274 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 65.82% of users gave Savara an outperform vote while only 50.00% of users gave Pharming Group an outperform vote.
0.0% of Pharming Group shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 4.6% of Savara shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Pharming Group has higher revenue and earnings than Savara. Pharming Group is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.
Pharming Group has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.
Pharming Group presently has a consensus target price of $37.00, indicating a potential upside of 283.82%. Savara has a consensus target price of $8.20, indicating a potential upside of 65.66%. Given Savara's higher possible upside, equities research analysts plainly believe Pharming Group is more favorable than Savara.
Savara has a net margin of 0.00% compared to Savara's net margin of -4.13%. Savara's return on equity of -4.53% beat Pharming Group's return on equity.
Summary
Savara beats Pharming Group on 8 of the 15 factors compared between the two stocks.
Get Savara News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
